Opus Genetics (IRD)
NASDAQ:IRD
IRD Stock Chart & Stats
$4.52
$0.08(5.63%)
At close: 4:00 PM EST
$4.52
$0.08(5.63%)
Day’s Range― - ―
52-Week Range$0.65 - $5.30
Previous CloseN/A
Volume154.21K
Average Volume (3M)1.01M
Market Cap
$321.59M
Enterprise Value$276.50M
Total Cash (Recent Filing)$45.09M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.43
Next Earnings
May 08, 2026EPS Estimate
-0.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.19
Shares Outstanding71,149,050
10 Day Avg. Volume1,043,003
30 Day Avg. Volume1,011,194
Financial Highlights & Ratios
PEG Ratio0.40
Price to Book (P/B)81.49
Price to Sales (P/S)88.10
P/FCF Ratio-35.48
Enterprise Value/Market Cap0.86
Enterprise Value/Revenue19.48
Enterprise Value/Gross Profit33.94
Enterprise Value/Ebitda-6.21
Forecast
1Y Price Target
$9.71Price Target Upside114.92% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-0.49
Revenue Forecast (FY)$15.56M
Bulls Say, Bears Say
Bulls Say
Clinical Efficacy And Anatomical ImprovementInitial patients showed marked reduction in retinal fluid and central retinal thickness coinciding with meaningful vision improvements, supporting the therapy's biological effect.
Funding And Development RunwayA financing round plus non-dilutive external funding strengthened the balance sheet and reduced near-term dilution risk, enabling progress toward key development milestones.
Safety And TolerabilityNo ocular inflammation or treatment-related serious adverse events were reported in the sentinel participant, indicating a clean safety and tolerability profile.
Bears Say
Financial Pressure And Execution RiskReported earnings missed estimates, underscoring that the company remains a development-stage story and may face financial pressure if programs require additional funding.
Limited Clinical DatasetOnly a small number of patients have been treated and early-phase data remain preliminary, so conclusions about safety and efficacy are tentative until larger cohorts are evaluated.
Uncertain Durability Of BenefitThe duration of observed clinical benefit is uncertain, leaving the long-term effectiveness and value of the therapies unproven.
Opus Genetics News
IRD FAQ
What was Opus Genetics’s price range in the past 12 months?
Opus Genetics lowest stock price was $0.65 and its highest was $5.30 in the past 12 months.
What is Opus Genetics’s market cap?
Opus Genetics’s market cap is $321.59M.
When is Opus Genetics’s upcoming earnings report date?
Opus Genetics’s upcoming earnings report date is May 08, 2026 which is in 42 days.
How were Opus Genetics’s earnings last quarter?
Opus Genetics released its earnings results on Mar 10, 2026. The company reported -$0.19 earnings per share for the quarter, missing the consensus estimate of -$0.112 by -$0.078.
Is Opus Genetics overvalued?
According to Wall Street analysts Opus Genetics’s price is currently Undervalued.
Does Opus Genetics pay dividends?
Opus Genetics does not currently pay dividends.
What is Opus Genetics’s EPS estimate?
Opus Genetics’s EPS estimate is -0.13.
How many shares outstanding does Opus Genetics have?
Opus Genetics has 71,149,050 shares outstanding.
What happened to Opus Genetics’s price movement after its last earnings report?
Opus Genetics reported an EPS of -$0.19 in its last earnings report, missing expectations of -$0.112. Following the earnings report the stock price went up 1.677%.
Which hedge fund is a major shareholder of Opus Genetics?
Currently, no hedge funds are holding shares in IRD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Opus Genetics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$9.71 (114.92% Upside)
$9.71 (114.92% Upside)
Blogger Sentiment
Bullish
IRD Sentiment 100%
Sector Average 69%
Sector Average 69%
Insider Transactions
Bought Shares
Worth $141.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.3%
Last 30 Days ▲ 14.4%
Last 30 Days ▲ 14.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
320.35%
12-Months-Change
Fundamentals
Return on Equity
-452.26%
Trailing 12-Months
Asset Growth
36.28%
Trailing 12-Months
Company Description
Opus Genetics
Opus Genetics, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. The company offers Phentolamine Ophthalmic Solution for reversal of mydriasis, as well as is in Phase III clinical trials for presbyopia and dim light or night vision disturbances. Its lead retinal product candidate is APX3330, a small-molecule inhibitor of reduction oxidation effector factor-1 protein that has completed Phase II clinical trial for the treatment of diabetic retinopathy. The company also develops APX2009 and APX2014 that are preclinical product candidates for retina indications. The company was formerly known as Ocuphire Pharma, Inc. Opus Genetics, Inc. was founded in 2018 and is headquartered in Farmington Hills, Michigan.
IRD Stock 12 Month Forecast
Average Price Target
$9.71
▲(114.92% Upside)
Technical Analysis
Ownership Overview
18.31% Insiders
3.42% Mutual Funds
26.00% Other Institutional Investors
48.94% Public Companies and Individual Investors
Options Prices
Currently, No data available
---